Literature DB >> 16218887

Syphilis treatment: old and new.

Linda Dayan1, Catriona Ooi.   

Abstract

Syphilis has challenged scientists and clinicians since its first appearance in the late 1400s and debate continues to surround the best practice in management. Difficulties in defining the goals of successful treatment have contributed to problems in determining recommendations for the ideal management. Treatment regimens currently in use were developed before randomised controlled trials became standard. This, combined with national differences in disease definition, staging and varying interpretations of the studies, as well as the emergence of complicating comorbid conditions, such as HIV, has resulted in a lack of consensus for treatment. This paper will discuss the history and current treatment of syphilis focusing on dilemmas faced by clinicians today, including the emergence of a resistant strain. Despite the difference between current national guidelines, penicillin G largely remains the treatment of choice. Close follow up, monitoring and ensuring adequate compliance remain the most important aspects in the treatment of syphilis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16218887     DOI: 10.1517/14656566.6.13.2271

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

1.  Syphilis, psychiatry and offending behaviour: clinical cases from nineteenth-century Ireland.

Authors:  B D Kelly
Journal:  Ir J Med Sci       Date:  2008-12-04       Impact factor: 1.568

2.  Ocular manifestations of syphilis: recent cases over a 2.5-year period.

Authors:  Cindy Puech; Stéphane Gennai; Patricia Pavese; Isabelle Pelloux; Max Maurin; Jean-Paul Romanet; Christophe Chiquet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-12       Impact factor: 3.535

Review 3.  Ecological and Evolutionary responses to Antibiotic Treatment in the Human Gut Microbiota.

Authors:  Joseph Hugh Pennycook; Pauline Deirdre Scanlan
Journal:  FEMS Microbiol Rev       Date:  2021-09-08       Impact factor: 16.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.